Clinical Trials Browser

Phase 1 × olutasidenib × 90 days × Clear all

NCT06543381 2026-03-05

Olutasidenib for the Treatment of Patients With IDH1 Mutated AML, MDS or CMML After Donor Hematopoietic Cell Transplant

Phase 1 Recruiting

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT07411586 2026-02-17

Phase 1/1b Trial Of Olutasidenib And Ziftomenib For NPM1 And IDH1 Co-Mutated Acute Myeloid Leukemia

Phase 1 Not yet recruiting

Other hematologic neoplasm

Leukemia, Myeloid, Acute